Teacher Retirement System of Texas Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Teacher Retirement System of Texas increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,075 shares of the biopharmaceutical company's stock after acquiring an additional 5,425 shares during the period. Teacher Retirement System of Texas' holdings in Alnylam Pharmaceuticals were worth $9,195,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. Allworth Financial LP increased its holdings in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after purchasing an additional 38 shares during the period. Nixon Peabody Trust Co. increased its stake in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after acquiring an additional 43 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 47 shares in the last quarter. Nwam LLC raised its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after acquiring an additional 50 shares in the last quarter. Finally, SYM FINANCIAL Corp boosted its position in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock valued at $260,000 after acquiring an additional 55 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on ALNY shares. Royal Bank of Canada upped their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research report on Friday, March 21st. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Monday, February 24th. Sanford C. Bernstein lowered their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Finally, Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $312.30.

Alnylam Pharmaceuticals Trading Down 4.2 %

ALNY traded down $11.75 during trading on Wednesday, hitting $269.21. 1,073,887 shares of the stock traded hands, compared to its average volume of 807,879. The firm has a 50-day moving average of $258.62 and a 200 day moving average of $260.26. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $34.85 billion, a P/E ratio of -124.06 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.